Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897291 | 0.86 | CLK4 (0.60) | CLK4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL4903567 | 0.85 | CLK4 (0.52) | CLK4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL14183668 | 0.83 | CLK4 (0.52) | CLK4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL23662309 | 0.82 | ADORA2A (0.57) | CLK4GRM5XDHIDO1DYRK1A | |
| SCHEMBL12171957 | 0.82 | MEN1 (0.64) | ALDH1A1LMNAMAP4K4ASIC3TSHR | |
| SCHEMBL12275241 | 0.81 | PLK1 (0.61) | MEN1KMT2A | |
| SCHEMBL16395695 | 0.79 | GRM5 (0.66) | CLK4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL9792898 | 0.78 | KMO (0.59) | CLK4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL15684019 | 0.77 | KMT2A (0.65) | CYP3A4ALDH1A1HSD17B10LMNAMAP4K4 | |
| SCHEMBL1143498 | 0.77 | MAP4K4 (0.54) | CLK4CYP3A4HSD17B10XDHMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315467-B2 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
| CN-101076337-A | Compounds for inhibiting nonsense mutations and methods of use thereof | PTC THERAPEUTICS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1799212-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044505-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | CLK4 3807/4885CYP1A2 4786/4885CYP3A4 4865/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | CLK4 4000/4885CYP1A2 4778/4885CYP3A4 4867/4885 |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | CLK4 4450/4885CYP1A2 4709/4885CYP3A4 4836/4885 |
| US-20160229818-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | CLK4 4450/4885CYP1A2 4709/4885CYP3A4 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.